Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.19
-0.02 (-0.28%)
Apr 8, 2026, 10:00 AM EDT - Market open
Karyopharm Therapeutics Analyst Ratings
Total Analysts
7
Consensus Rating
Strong Buy
Price Target
$14.67
Upside
+104.03%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $12 → $8 | Buy | Reiterates | $12 → $8 | +11.27% | Mar 30, 2026 |
| Baird | Baird | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +108.62% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $8 | Strong Buy | Maintains | $15 → $8 | +11.27% | Mar 25, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +289.43% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +108.62% | Feb 18, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $30 → $19 | Buy | Maintains | $30 → $19 | +164.26% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $15 | Hold → Strong Buy | Upgrades | $15 | +108.62% | Oct 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $15 → $12 | Buy | Reiterates | $15 → $12 | +66.90% | Oct 9, 2025 |
| Baird | Baird | Buy Maintains $25 → $21 | Buy | Maintains | $25 → $21 | +192.07% | Oct 9, 2025 |
| Baird | Baird | Buy Maintains $42 → $25 | Buy | Maintains | $42 → $25 | +247.71% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +275.52% | Jul 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +358.97% | May 13, 2025 |
| Barclays | Barclays | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +39.08% | May 13, 2025 |
| Baird | Baird | Buy Maintains $54 → $42 | Buy | Maintains | $54 → $42 | +484.14% | May 13, 2025 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.